Aprea Therapeutics (APRE) Competitors $1.92 +0.09 (+4.92%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. LIAN, ITRM, XLO, OKUR, KPTI, MDCX, ESLA, ELYM, PLUR, and ACRVShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include LianBio (LIAN), Iterum Therapeutics (ITRM), Xilio Therapeutics (XLO), OnKure Therapeutics (OKUR), Karyopharm Therapeutics (KPTI), Medicus Pharma (MDCX), Estrella Immunopharma (ESLA), Eliem Therapeutics (ELYM), Pluri (PLUR), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors LianBio Iterum Therapeutics Xilio Therapeutics OnKure Therapeutics Karyopharm Therapeutics Medicus Pharma Estrella Immunopharma Eliem Therapeutics Pluri Acrivon Therapeutics LianBio (NASDAQ:LIAN) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Does the media favor LIAN or APRE? In the previous week, Aprea Therapeutics had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Aprea Therapeutics and 0 mentions for LianBio. Aprea Therapeutics' average media sentiment score of 0.44 beat LianBio's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment LianBio Neutral Aprea Therapeutics Neutral Is LIAN or APRE more profitable? LianBio has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. LianBio's return on equity of -33.17% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LianBioN/A -33.17% -30.19% Aprea Therapeutics -1,029.50%-57.86%-47.94% Do analysts prefer LIAN or APRE? Aprea Therapeutics has a consensus target price of $15.50, indicating a potential upside of 707.29%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of LIAN or APRE? 74.8% of LianBio shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, LIAN or APRE? LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Which has stronger earnings & valuation, LIAN or APRE? Aprea Therapeutics has higher revenue and earnings than LianBio. Aprea Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLianBioN/AN/A-$110.29M-$0.81-0.46Aprea Therapeutics$580K18.31-$14.29M-$2.37-0.81 Does the MarketBeat Community favor LIAN or APRE? Aprea Therapeutics received 52 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 57.14% of users gave Aprea Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote. CompanyUnderperformOutperformLianBioOutperform Votes436.36% Underperform Votes763.64% Aprea TherapeuticsOutperform Votes5657.14% Underperform Votes4242.86% SummaryAprea Therapeutics beats LianBio on 11 of the 17 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.62M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.688.7927.2619.97Price / Sales18.31263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.426.597.064.69Net Income-$14.29M$144.20M$3.24B$248.14M7 Day Performance6.08%3.81%2.56%2.39%1 Month Performance23.87%11.10%8.75%6.06%1 Year Performance-54.82%3.95%31.30%13.57% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics3.2411 of 5 stars$1.92+4.9%$15.50+707.3%-57.8%$10.62M$580K-0.687Short Interest ↑Gap UpLIANLianBioN/A$0.36flatN/A+15.3%$38.90MN/A-0.44110ITRMIterum Therapeutics2.3793 of 5 stars$0.97-3.0%$9.00+827.9%-11.9%$38.80MN/A-0.7410News CoverageXLOXilio Therapeutics3.553 of 5 stars$0.70-34.6%$4.00+471.3%-38.1%$36.25M$9.27M-0.4170Short Interest ↓Gap DownHigh Trading VolumeOKUROnKure Therapeutics3.6549 of 5 stars$2.65+4.7%$32.33+1,120.1%N/A$35.80MN/A-0.22N/ANews CoveragePositive NewsKPTIKaryopharm Therapeutics4.037 of 5 stars$4.12-1.9%$43.20+948.5%-71.0%$35.60M$142.13M-4.04380MDCXMedicus Pharma2.0254 of 5 stars$2.63+3.1%$23.50+793.5%N/A$35.49MN/A0.00N/AAnalyst ForecastHigh Trading VolumeESLAEstrella Immunopharma2.121 of 5 stars$0.98-2.9%$16.00+1,532.7%+14.3%$35.44MN/A-3.77N/AShort Interest ↑Gap DownELYMEliem TherapeuticsN/A$1.18-3.3%N/A-83.5%$35.11MN/A-2.239PLURPluri2.0682 of 5 stars$4.47+0.2%$12.00+168.5%-20.8%$35.01M$1.03M-0.80150Short Interest ↑Gap DownACRVAcrivon Therapeutics4.2611 of 5 stars$1.11+5.7%$17.71+1,495.9%-82.8%$34.80MN/A-0.4158Positive NewsAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies LIAN Competitors ITRM Competitors XLO Competitors OKUR Competitors KPTI Competitors MDCX Competitors ESLA Competitors ELYM Competitors PLUR Competitors ACRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APRE Stock Free APRE Stock Alerts